Welcome to our dedicated page for Chemomab Therapeutics Ltd. American Depositary Share news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics Ltd. American Depositary Share stock.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotechnology company focused on the development of innovative therapeutics to treat fibro-inflammatory diseases with significant unmet medical needs. The company's proprietary platform centers on CM-101, a first-in-class monoclonal antibody that targets the protein CCL24, a key regulator of inflammatory and fibrotic pathways in several severe diseases.
CM-101 has demonstrated potential in disrupting the underlying biology of fibrosis through a novel mechanism of action. The company is actively advancing CM-101 through multiple Phase 2 clinical trials aimed at treating rare and life-threatening conditions such as primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH), and systemic sclerosis (SSc). In recognition of its innovative approach, CM-101 has been granted Orphan Drug designation in both the U.S. and the European Union, and it recently received Fast Track designation from the FDA for PSC treatment.
Chemomab has reported encouraging preliminary results from these trials, which indicate that CM-101 is safe and effective in interfering with fibrotic and inflammatory pathways. The company has secured robust intellectual property protections for CM-101, with patents granted or pending in major territories worldwide, ensuring proprietary rights for the treatment of multiple indications until at least 2038.
Recent highlights from Chemomab include:
- Completion of patient enrollment in the Phase 2 PSC trial, with topline data expected mid-2024.
- Granting of new patents in Brazil, Israel, and Europe that further protect the use of CM-101 in treating liver diseases and other conditions.
- Publication of peer-reviewed studies validating the role of CCL24 in driving PSC and SSc pathologies, and the potential of CM-101 as a therapeutic intervention.
- Presentations at major scientific conferences including EASL 2024 and the Gordon Research Conference, showcasing novel translational assays and proteomic profiling studies that support the efficacy of CM-101.
As Chemomab continues to advance its clinical programs and expand its scientific understanding of fibro-inflammatory diseases, it remains committed to addressing the urgent need for effective treatments in these challenging medical areas.
Chemomab Therapeutics Ltd (Nasdaq: CMMB), a clinical-stage biotechnology company, will participate in the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 29, 2022. Co-founder and Chief Scientific Officer Adi Mor will be a panelist. The discussion will focus on 'Platforms and Pipelines in a Product', highlighting potential applications across various rare diseases. Chemomab specializes in innovative therapies for fibrotic and inflammatory diseases, with their lead product, CM-101, in Phase 2 trials for multiple conditions.
Chemomab Therapeutics (Nasdaq: CMMB) presented significant findings regarding its lead candidate, CM-101, at recent conferences in Israel. Data indicated that CCL24 levels were elevated in patients with diffuse cutaneous systemic sclerosis (dcSSc), correlating with disease activity and poor prognosis. The company plans to initiate a Phase 2 trial for CM-101 later this year, aiming to target CCL24 to address unmet needs in systemic sclerosis, a serious autoimmune disease.
Chemomab Therapeutics, Ltd. (CMMB) reported its fourth quarter and full-year 2021 financial results, showcasing a cash position of $61.2 million compared to $11.8 million in 2020. R&D expenses rose to $2.4 million for Q4 and $6.3 million for the year, while G&A expenses increased to $2.6 million for Q4 and $6.0 million for the year. The net loss was $5.0 million for Q4, totaling $12.5 million for 2021. Significant clinical program revisions were announced, aimed at optimizing the development of CM-101, including expanded trials for PSC and SSc, with more data readouts expected over the next 24 months.
Chemomab Therapeutics (CMMB) will announce its fourth quarter and full year 2021 financial results on March 9, 2022. The company focuses on developing therapeutics for fibrotic and inflammatory diseases. A conference call will be held at 8:00 a.m. Eastern Time to discuss performance and upcoming events. Chemomab's key product, CM-101, is currently undergoing two Phase 2 trials with a third set to start in early 2022. This innovative approach targets the CCL24 protein, which is central to fibrosis and inflammation.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company, announced it will present at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 9:00 am ET. The company focuses on innovative therapeutics for fibrotic and inflammatory diseases, highlighting its monoclonal antibody CM-101, designed to block the soluble protein CCL24, which is linked to these conditions. CM-101 is currently undergoing two Phase 2 trials for primary sclerosing cholangitis and liver fibrosis, with a third trial in systemic sclerosis anticipated to start in early 2022.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced the appointment of Jack Lawler as Vice President of Global Clinical Development Operations, enhancing its clinical development leadership. Lawler brings over 22 years of experience in drug development, previously contributing to eight approved pharmaceuticals. Chemomab has also expanded its facilities in Tel Aviv to support anticipated growth. The company focuses on developing CM-101, a monoclonal antibody aimed at addressing serious fibrotic and inflammatory diseases, currently in two Phase 2 trials.
Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) announced participation in two key virtual events: the LifeSci Partners 11th Annual Corporate Access Event from January 5-7, 2022, featuring 1-on-1 meetings, and the H.C. Wainwright BioConnect Conference from January 10-13, 2022, offering an on-demand corporate overview webcast. Chemomab focuses on therapeutics for fibrotic and inflammatory diseases, with its lead candidate, CM-101, in Phase 2 trials targeting multiple severe conditions. For event registration and additional details, visit Chemomab's website.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) has announced that CEO Dale R. Pfost will take on the role of Chairman, pending shareholder approval expected in February 2022. Stephen Squinto will step down from his role as Chairman and director on December 19, 2021. Dr. Pfost expressed excitement for the company's Phase 2 clinical programs in liver fibrosis and systemic sclerosis. Chemomab is developing CM-101, a monoclonal antibody targeting CCL24, currently undergoing clinical trials for severe fibrotic and inflammatory diseases.
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) announced the appointment of David M. Weiner, MD, as Interim Chief Medical Officer, effective immediately. He replaces Dr. Arnon Aharon, who will remain for a 60-day transition period. Dr. Weiner brings over 25 years of biopharmaceutical experience and has held senior roles at various biotech companies. He aims to advance Chemomab's clinical programs, particularly for CM-101, a monoclonal antibody in Phase 2 trials targeting fibrotic diseases. The company acknowledges Dr. Aharon's contributions to its clinical advancements.
Chemomab Therapeutics (CMMB) announced its third-quarter financial results for 2021, revealing a significant cash position of $64.3 million, which is expected to fund operations until mid-2023. The company reported a net loss of $3.0 million, or ($0.01) per share, compared to a loss of $1.2 million in the previous year. Key updates included advancements in clinical trials for CM-101 aimed at treating fibrotic diseases and the appointment of Donald Marvin as CFO. Upcoming data readouts from ongoing Phase 2 trials are anticipated in 2022, suggesting potential growth for Chemomab's pipeline.
FAQ
What is the current stock price of Chemomab Therapeutics Ltd. American Depositary Share (CMMB)?
What is the market cap of Chemomab Therapeutics Ltd. American Depositary Share (CMMB)?
What is Chemomab Therapeutics Ltd.?
What is CM-101?
What diseases is CM-101 being tested for?
Has CM-101 received any special designations from regulatory authorities?
When are the results from the Phase 2 PSC trial expected?
What recent achievements has Chemomab announced?
What makes CM-101 unique?
What is the significance of the new patents granted to Chemomab?
Where has Chemomab presented its research?
How does CM-101 work?
